Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months in 44% of patients Safety and durability profile consistent with known mechanism of action Early signals support advancement to a Phase 2 a clinical trial with...

TransCode Therapeutics acquires Polynoma LLC and receives $25M investment from CK Life Sciences to develop innovative cancer therapies, including melanoma vaccine and microRNA treatments.

YouTube video by Rutiger o'sullivan

YouTube video by Kelso Guitar Vibes

YouTube video by Rutiger o'sullivan

TransCode Therapeutics (NASDAQ: RNAZ) has announced successful completion of initial dosing in Cohort 4 of its Phase 1a clinical trial for TTX-MC138. Key highlights include: - 15 patients treated across 4 dose levels (0.8 mg/kg to 4.8 mg/kg) - No significant safety or dose-limiting toxicities reported - 10 patients remain on study with stable disease - Two patients received 7 doses over ~7 months showing stable disease - PK/PD data shows predictable dose-response relationship - Evidence of miR-10b target engagement at 24 hours post-infusion in Cohorts 1 and 2 - Safety Review Committee approved expanded enrollment in Cohort 3 The positive results support advancement to the Phase 1b dose expansion portion of the trial.

Major stock consolidation reduces 23.3M shares to 833K. See how this reverse split impacts your holdings and TransCode's Nasdaq listing status. Get details.

TransCode's reverse split will convert 23.3M shares to 833.6K, aiming for Nasdaq minimum bid compliance. See how this impacts your holdings.